Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
Summary
Background
COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK.
Methods
We did a prospective, multicentre cohort study in 302 UK health-care facilities. Adult patients aged 19 years or older, with confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 were included in the study. The primary outcome of this study was the incidence of in-hospital complications, defined as organ-specific diagnoses occurring alone or in addition to any hallmarks of COVID-19 illness. We used multilevel logistic regression and survival models to explore associations between these outcomes and in-hospital complications, age, and pre-existing comorbidities.
Findings
Between Jan 17 and Aug 4, 2020, 80 388 patients were included in the study. Of the patients admitted to hospital for management of COVID-19, 49·7% (36 367 of 73 197) had at least one complication. The mean age of our cohort was 71·1 years (SD 18·7), with 56·0% (41 025 of 73 197) being male and 81·0% (59 289 of 73 197) having at least one comorbidity. Males and those aged older than 60 years were most likely to have a complication (aged ≥60 years: 54·5% [16 579 of 30 416] in males and 48·2% [11 707 of 24 288] in females; aged <60 years: 48·8% [5179 of 10 609] in males and 36·6% [2814 of 7689] in females). Renal (24·3%, 17 752 of 73 197), complex respiratory (18·4%, 13 486 of 73 197), and systemic (16·3%, 11 895 of 73 197) complications were the most frequent. Cardiovascular (12·3%, 8973 of 73 197), neurological (4·3%, 3115 of 73 197), and gastrointestinal or liver (10·8%, 7901 of 73 197) complications were also reported.
Interpretation
Complications and worse functional outcomes in patients admitted to hospital with COVID-19 are high, even in young, previously healthy individuals. Acute complications are associated with reduced ability to self-care at discharge, with neurological complications being associated with the worst functional outcomes. COVID-19 complications are likely to cause a substantial strain on health and social care in the coming years. These data will help in the design and provision of services aimed at the post-hospitalisation care of patients with COVID-19.
Funding
National Institute for Health Research and the UK Medical Research Council.
Introduction
- Docherty AB
- Harrison EM
- Green CA
- et al.
Several case reports, cross-sectional studies, and case-control studies have described the presence of non-respiratory complications in those with COVID-19 and suggest that these are likely to be associated with poor outcomes.
- Carfì A
- Bernabei R
- Landi F
,
- Paterson RW
- Brown RL
- Benjamin L
- et al.
,
- Puntmann VO
- Carerj ML
- Wieters I
- et al.
Understanding the possible complications of COVID-19 is important for patient management and provision in health-care systems. For patients, information around in-hospital complication rates are important for decision making about treatment, long-term planning, possible resumption of normal activity and, more recently, vaccination. For health-care systems, these data are vital to inform immediate preparedness measures (ie, allocation of resources, equipment, and staffing) and also for long-term planning of health-care delivery to a population that might have incurred additional morbidity due to COVID-19.
Evidence before this study
We did a systematic search of the MEDLINE and PubMed databases on Dec 5, 2020, using the search terms (“in-hospital” OR “hospital”) AND (“SARS-CoV-2” OR “COVID” OR “COVID-19”) AND “complications”. We limited dates of searches from Jan 1, 2020, to the date the search was conducted. No language restrictions applied. Data from other areas of health care, such as surgery, suggest that patients with COVID-19 are at greater risk of subsequent complications, but systematic characterisation of complications in these patients has not yet been undertaken in large multicentre studies of patients admitted to hospital. Most COVID-19 studies have focused on mortality and respiratory support outcomes. Characterising the burden of complications is important for health-care system preparedness for further waves of infection, determining future population morbidity, understanding the full repercussions of COVID-19 for society, and for informing future research and clinical guidelines. The current literature is comprised of several small cohort or case-control studies that focus on specific organ systems or conditions. There are few prospective systematically collected data describing the in-hospital complications of COVID-19.
Added value of this study
Hospitalised adult patients aged 19 and over with COVID-19 frequently had complications, even in younger age groups and in those with few pre-existing comorbidities. Occurrence of complications was associated with a significantly reduced ability to self-care at discharge, which was seen in all age and comorbidity groups. Although patients aged younger than 50 years are at low risk of dying from COVID-19, we found high rates of complications across all age groups.
Implications of all the available evidence
In patients admitted to hospital with COVID-19, there is a burden of immediate complications affecting all age groups. Many of the complications identified are likely to have important long-term effects. Health-care systems and policy makers should prepare for increases in population morbidity arising from COVID-19 and its subsequent complications. As complications following COVID-19 are common across all age groups and comorbidities, public health messaging around the risk COVID-19 poses to younger otherwise healthy people should be considered alongside vaccine prioritisation. Further studies are required to understand the medium-term to long-term effects of COVID-19 and how immediate complications may lead to lasting morbidity.
- Needham DM
- Feldman DR
- Kho ME
,
- Lone NI
- Gillies MA
- Haddow C
- et al.
Mortality has been widely used as an outcome in epidemiological studies and randomised controlled trials for patients with COVID-19 but fails to capture the immediate short-term health issues faced by survivors, including in-hospital complications and functional outcomes. In patients with COVID-19 undergoing surgery, high rates of post-procedural mortality and complications have been noted, but systematic characterisation of hospitalised patients with COVID-19 is lacking.
- Nepogodiev D
- Bhangu A
- Glasbey JC
- et al.
In other non-SARS-CoV-2 viral illnesses, for example influenza, short-term complications such as myocardial infarction, acute kidney injury, and stroke are common and can cause greater morbidity than the initial infection itself.
- Lone NI
- Gillies MA
- Haddow C
- et al.
,
- Docherty AB
- Sim M
- Oliveira J
- et al.
,
- Chapman AR
- Shah ASV
- Lee KK
- et al.
,
- Heyland DK
- Groll D
- Caeser M
,
- Warren-Gash C
- Blackburn R
- Whitaker H
- McMenamin J
- Hayward AC
Understanding which patients develop short-term complications might also allow clinicians and researchers to develop care pathways and interventions to mitigate the impact of complications. As many patients with COVID-19 are critically unwell, identifying the burden of short-term morbidity could be useful to understand the long-term burden on health-care systems and society for those who survive COVID-19.
- Docherty AB
- Harrison EM
- Green CA
- et al.
The aim of this study was to describe the short-term complications, beyond those associated with the presenting features of COVID-19 and severe acute respiratory infection.
Methods
Study design and participants
- Dunning JW
- Merson L
- Rohde GGU
- et al.
Our study is an actively recruiting prospective cohort study across 302 health-care facilities in the UK. Adult patients aged 19 years and older, who were admitted to hospital between Jan 17 and Aug 4, 2020, with confirmed or highly suspected SARS-CoV-2 infection leading to COVID-19 were included in this analysis; overall study recruitment is ongoing. We used this WHO age cutoff
Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19.
as children exhibit other patterns of complications including multisystem inflammatory syndrome. Confirmation of SARS-CoV-2 was done using RT-PCR. Highly suspected cases were eligible for inclusion, given that SARS-CoV-2 was an emergent pathogen at the time of protocol activation and laboratory confirmation was dependent on local availability of testing.
Site set-up.
All patients who provided biological samples were required to provide informed, written consent. If patients only provided routinely collected clinical data, written consent was not required. Ethical approval was given by the South Central–Oxford C Research Ethics Committee in England (reference 13/SC/0149) and the Scotland A Research Ethics Committee (reference 20/SS/0028). The study is reported in line with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.
- Von Elm E
- Altman DG
- Egger M
- Pocock SJ
- Gøtzsche PC
- Vandenbroucke JP
Procedures
- Harris PA
- Taylor R
- Thielke R
- Payne J
- Gonzalez N
- Conde JG
Multiple timepoints were captured, including admission, hospital stay at days 1, 3, and 9, and discharge or status at 28 days if not discharged. Data were collected according to a detailed protocol, which was updated to reflect developments over the course of the pandemic. Participant characteristics including age, sex at birth, physiological parameters at presentation, and comorbidities were also recorded. Comorbidities included asthma, chronic cardiac disease, chronic haematological disease, chronic kidney disease, chronic neurological disease, chronic pulmonary disease, HIV/AIDS, history of malignancy, liver disease, clinician-defined obesity, rheumatological disorders, and smoking. Deprivation was calculated by mapping individual postcodes to their corresponding Index of Multiple Deprivation (IMD) using the Office for National Statistics postcode data. Using national data, we calculated deprivation quintiles, with the first quintile being the least deprived and the fifth quintile the most deprived. For patients where postcodes were missing, the average IMD rank, weighted by population in each lower super output area for a given hospital catchment area, was used.
Outcomes
- Kellum JA
- Lameire N
- Aspelin N
- et al.
(creatinine rise ≥1·5 × baseline value or by ≥26·5 μmol/L). We did not incorporate urine output into this definition as this parameter is not universally recorded for all patients, particularly outwith critical care. Acute liver injury was defined as one of the following: an international normalised ratio rise of 2·5 times or greater than the lowest entered value; an international normalised ratio of more than 4·5 (in the absence of warfarin therapy); an alanine aminotransferase rise of more than 10 times the lowest value; an alanine aminotransferase of more than 150 IU/L; a bilirubin rise of more than 15 μmol/L; or a bilirubin greater than 55 μmol/L (in the absence of any pre-existing liver disease). In those who survived, we also captured information on whether self-care ability was the same or worse than before hospital admission at time of discharge, defined clinically as the change in support required before and after hospital admission. For this outcome, if patients required ongoing hospital care, we defined this outcome as worse than before onset of COVID-19 illness due to these ongoing care requirements.
Statistical analysis
Continuous data are presented as a mean with SD where data are normally distributed and as a median with the 25th and 75th centiles for non-parametric data. Categorical data are summarised as frequencies and percentages. Differences between groups for continuous normally distributed data were tested using Welch’s t test for two groups or ANOVA when there were more than two groups. Non-parametric continuous data were tested using a Mann-Whitney U test for two groups or Kruskall-Wallis test for three or more groups. Differences across categorical data were tested using the χ2 test or Fisher’s exact test when expected cell counts were less than five. Analysis of complication co-occurrence was done using the Jaccard similarity index and represented visually as heatmaps with dendrograms constructed from complete hierarchical clustering results. We only included patients who had completed outcomes, with at least 2 months of follow-up. There were low rates of missing data and therefore multiple imputation was not used.
To explore if the number of complications and which specific complications were associated with mortality (dependent variable), complication variables were entered independently into Cox proportional hazards models and adjusted for other potentially confounding factors. These data were described using Kaplan-Meier plots and modelled using Cox proportional hazards regression. Reported date of symptom onset was taken as day 0. Discharge from hospital was considered an absorbing state (once discharged, patients were considered no longer at risk of death); thus discharge did not compete with death. The proportional hazards assumption was checked.
- Knight SR
- Ho A
- Pius R
- et al.
These scores are commonly used in clinical practice to identify patients with deteriorating or critical illness and risk of subsequent death in general adult hospital populations (NEWS2 and qSOFA) or in COVID-19 patients (4C Mortality Score). We calculated the score for each adult patient in the dataset and plotted each score against the observed incidence of complications in each score group.
Multilevel logistic regression models were constructed to identify associations between patient characteristics (potential confounders, including patient demographics and existing comorbidities) and the development of specific complications, worse self-care ability on discharge, and the requirement for ongoing hospital care. For all models, variable selection was done based on clinical plausibility, and final models were selected based on clinical relevance guided by minimisation of the Akaike information criterion. Centre-level variation was accounted for using mixed-effects models that included hospital as a random effect and patient-level variables as fixed effects. We did stratified analyses to focus on survivors and on those admitted to critical care.
To identify which patient groups are at the highest risk of complications and mortality, we used generalised additive models and generated risk estimates by age, sex, and comorbidity status. Generalised additive models accommodated potential non-linear relationships between variables with the inclusion of penalised thin-plate regression splines on continuous variables. We did this for each organ-specific complication outcome, as well as testing the associations between organ-specific complications and death. Models were adjusted for age, sex, comorbidity status and deprivation (IMD quintile). First and second order interactions were explored and included where they significantly contributed to model fitting. We ran 100 bootstrap replicates for each model to provide a visual representation of the distribution.
All statistical analyses were done with R (version 3.6.3) using the tidyverse, finalfit, mcgv, survival, stringdist, janitor, and Hmisc packages.
Role of the funding source
The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Results
Table 1Patient characteristics by organ-specific complications
Data are n or n (%). No means patients didn’t have the comorbidity or characteristic, yes means they did. IMD=Index of Multiple Deprivation.
Figure 2Outcomes and mortality after complications
Figure 3Relationship between age, sex, comorbidities, and adjusted outcomes using generalised additive models
Table 2Outcomes by organ-specific complications
Data are n or n (%). No means patients did not have the clinical outcome specified in the table rows, yes means they did.
Figure 4Relationship between in-hospital complications and ability to self-care at time of discharge or transfer to other health-care facility
Discussion
Hospitalisation with COVID-19 is associated with high rates of morbidity in adults. Almost half of the survivors had one or more complications, which were more likely in patients who required critical care. Survivors of COVID-19 who had suffered at least one complication had a lower ability to self-care on discharge from hospital. The effect of complications on the ability to self-care was most profound in younger patients (aged <50 years). We found that complication rates were high in every age group and increased with age. Unlike mortality, there were only small differences in complication rates in groups stratified by pre-existing comorbidity. Males were significantly more likely to develop complications than females.
,
- Odutayo A
- Wong CX
- Farkouh M
- et al.
,
- Parikh CR
- Coca SG
- Wang Y
- Masoudi FA
- Krumholz HM
In addition to the more common complications identified, rarer complications including stroke, congestive heart failure, and cardiac arrest were present in 1–5% of patients.
- James SL
- Abate D
- Abate KH
- et al.
,
- Feigin VL
- Nichols E
- Alam T
- et al.
,
- Phelps R
- Dumas F
- Maynard C
- Silver J
- Rea T
Patients who received critical care had the highest complication rates, compatible with previous observations describing high levels of morbidity in those who require critical care.
- Lone NI
- Gillies MA
- Haddow C
- et al.
,
- Docherty AB
- Sim M
- Oliveira J
- et al.
,
- Adhikari NKJ
- Fowler RA
- Bhagwanjee S
- Rubenfeld GD
,
- Girling BJ
- Channon SW
- Haines RW
- Prowle JR
The least commonly observed were neurological complications, although these were the most strongly associated with reduced ability to self-care. Suspected bacterial pneumonia and likely ARDS were the most common respiratory complications. When compared with the published literature on influenza, complications rates in patients with COVID-19 were the same or higher.
- Martin-Loeches I
- Papiol E
- Rodríguez A
- et al.
,
- Papic N
- Pangercic A
- Vargovic M
- Barsic B
- Vince A
- Kuzman I
,
Notably, this higher rate of complications appears to be primarily driven by non-infectious complications, as the rates of secondary bacterial infection in patients with COVID-19 were lower than described in influenza.
- Klein EY
- Monteforte B
- Gupta A
- et al.
In particular, COVID-19 patients had up to 19 times the risk of developing likely ARDS when compared with patients admitted with influenza.
- Cates J
- Lucero-Obusan C
- Dahl RM
- et al.
- Docherty AB
- Harrison EM
- Green CA
- et al.
Mortality is a hard endpoint, easily measured, and of utmost importance. However, its use as a sole outcome in COVID-19 studies might underestimate the detrimental impact of COVID-19, particularly in those who are younger or otherwise healthy. Our analysis suggests that the odds of some complications change little with increasing age in those older than 50 years. Therefore, when compared with mortality, complications will affect many more people across a range of different age groups. Notably, our data show only small increases in the risk of complications by pre-existing comorbidities. The effect of comorbidities on the risk of complications and death was substantially higher in younger people compared with people without comorbidities of the same age. We also observed the differences in number of complications decrease between those who died and those who survived as age increased, suggesting that although young people are less likely to die, they might be proportionally more likely to survive and live with complications. Patients with complications are also likely to have impaired ability to self-care following discharge from hospital. This finding contradicts current narratives that COVID-19 is only dangerous in people with existing comorbidities and the elderly. Dispelling and contributing to the scientific debate around such narratives has become increasingly important. Many countries including the UK are experiencing further waves of infection.
Weekly coronavirus disease 2019 (COVID-19) surveillance report—summary of COVID-19 surveillance systems.
Suggestions have been made around using younger, healthy demographic groups who are less likely to die, to help support economic output, and to propagate herd immunity within a population.
Coronavirus: top scientists call for herd immunity approach—as government’s ‘soft touch’ criticised.
Policy makers need to consider not just mortality when making decisions around easing population-level interventions designed to limit spread, but also the risk of both short-term and long-term complications for those who survive COVID-19.
- Puntmann VO
- Carerj ML
- Wieters I
- et al.
,
- Hendren NS
- Drazner MH
- Bozkurt B
- Cooper Jr, LT
,
- Alqahtani SA
- Schattenberg JM
,
- El Moheb M
- Naar L
- Christensen MA
- et al.
,
,
- Casas-Aparicio GA
- León-Rodríguez I
- Alvarado-de CLB
- et al.
Our study identifies high rates of complications and the risk factors for developing these, and describes severity, which previous studies have been unable to do at scale. In particular, we find that in the short term, respiratory and cardiovascular complications have the strongest association with mortality. A further strength is that our study includes patients in both critical care and in ward-level areas, whereas other groups have just studied intensive care populations.
COVID-19 reports.
In addition, the multicentre nature of our study across 302 facilities in four countries increases the generalisability of our findings, which is particularly important to provide robust estimates of short-term morbidity for health-care planners and policy makers. The large sample size of our study allowed us to do meaningful subgroup analyses and integrate blood test and microbiology results to increase robustness. This size also meant we could detect rare events in important patient groups such as those receiving critical care, younger patients, and survivors where complications might have the biggest effect and be with patients for a long period of time after the initial event.
- Llitjos JF
- Leclerc M
- Chochois C
- et al.
We found initial disease severity, measured using the 4C Mortality Score, qSOFA, and NEWS, were associated with the presence of complications, and could therefore be useful tools to stratify those at the highest risk of developing complications in clinical practice and interventional trials.
- Khan MS
- Shahid I
- Anker SD
- et al.
This protocol did not include a non-SARS-CoV-2 comparator group, which could provide useful data to compare complication burdens to other causes of critical illness or viral infection. Third, owing to logistical constraints, we did not capture data on the timings of each complication. As our study was an urgent response to the emerging pandemic, it would not have been possible to identify exactly when each complication started for such a large number of patients. Data around timings could in the future help to identify sequences of events that lead to further deterioration. Fourth, our data can only provide estimates of who gets complications in a hospitalised population. We found that even in previously healthy adults with no recorded comorbidity, complications affected more than four in ten hospitalised patients; the effect and burden in the community remains undescribed. For infection-related outcomes, we systematically classified microbiological culture results to identify whether infections were caused by pathogenic organisms. However, individuals might have acquired these in the community, so our estimates encompass both hospital and community acquired infection. In addition to this, the UK health service was under considerable pressure, which could have resulted in preferential admission to hospital of patients with the most severe disease. This might lead to an increase in the observed complication rate, as individuals with milder disease were managed at home. However, the risk of this is reduced by the multicentre design of our study, as peaks in hospital admissions varied in the UK over time. Compared with other international cohorts, our study had a higher observed hospital case fatality rate.
,
- Nachtigall I
- Lenga P
- Jóźwiak K
- et al.
,
- Bellan M
- Patti G
- Hayden E
- et al.
,
- Piroth L
- Cottenet J
- Mariet AS
- et al.
The reasons for this are multifactorial, and could relate to differences in testing strategy, thresholds for hospital admission, pre-existing population morbidity, and health-care system preparedness. Finally, our data were collected from real-world observed clinical practice and patients did not undergo any additional tests to detect the presence of complications. Therefore, the true burden of complications is likely to be higher. However, doing large numbers of invasive tests might not be acceptable for patients, particularly in patients who are unlikely to survive or cannot tolerate investigations, and would be logistically challenging in a study of this size.
Policy makers and health-care planners should anticipate that large amounts of health and social care resources will be required to support those who survive COVID-19. This includes adequate provision of staffing and equipment; for example, provision of follow-up clinics for those who have sustained in-hospital complications such as acute kidney injury or respiratory tract infection. Beyond the short term, further work is underway to establish the consequences of these complications and whether these are transient or linked to worse long-term outcomes. Data on long-term health difficulties posed by COVID-19 will be of great importance, particularly as a large proportion of COVID-19 survivors come from economically active age groups. This should be considered on a policy level in terms of return to work and education; but importantly, it could have effects on individual behaviour around perceived benefits of engaging with preventive measures including vaccination.
In summary, high rates of complications and poor functional outcomes were present in survivors of COVID-19, including in young and previously healthy individuals. Those aged older than 50 years and admitted to critical care were at the highest risk. Common COVID-19 complications identified in this Article are known to be associated with long-term morbidity and an increased risk of death.
This online publication has been corrected. The corrected version first appeared at thelancet.com on July 29, 2021
Contributors
TMD, AMR, EMH, ABD, and MGS were responsible for the conception of analysis, data analysis, and data interpretation, as well as the writing and revision of the manuscript. CE, RP, and LN analysed the data. HEH, DP, KAH, LM, LS, MG, CJ, PO, and GC designed and coordinated the study. CJF, SRK, CAS, KAM, AH, CDR, TS, LT, JSN-V-T, and PJMO interpreted the data, and were responsible for writing and revising the manuscript. AART, FS, OVS, MS, TIdS, JD, JKB, and MGS interpreted the data, and wrote and critically reviewed the manuscript. All authors critically reviewed and revised the draft the manuscript. TMD, AMR, ABD, LN, RP, and EMH all had access to the underlying data and verified the findings. TMD, EMH, and MGS were responsible for manuscript submission. All authors have seen and approved the final version. TMD, AMR, RP, JKB, ABD, MGS and EMH had access to the raw data. The corresponding author had full access to all data and the final responsibility to submit for publication.
ISARIC4C investigators
United Kingdom: J Kenneth Baillie, Fiona Griffiths, Wilna Oosthuyzen, Andrew Law, Sara Clohisey, Ross Hendry (Roslin Institute, University of Edinburgh). Malcolm G Semple, Tom Solomon, Lance CW Turtle, Hayley Hardwick (National Institure for Health Research [NIHR] Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool). Peter JM Openshaw, Ryan S Thwaites (National Heart and Lung Institute, Imperial College London). Gail Carson, Laura Merson, Louise Sigfrid (ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford). Beatrice Alex, Benjamin Bach, James Scott-Brown (School of Informatics, University of Edinburgh). Wendy S Barclay (Section of Molecular Virology, Imperial College London). Debby Bogaert, Clark D Russell (Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh). Meera Chand (Antimicrobial Resistance and Hospital Acquired Infection Department, Public Health England). Graham S Cooke, Shiranee Sriskandan (Department of Infectious Disease, Imperial College London). Annemarie B Docherty, Ewen M Harrison, Lisa Norman, Riinu Pius, Thomas M Drake, Cameron J Fairfield, Stephen R Knight, Kenneth A Mclean, Derek Murphy, Catherine A Shaw (Centre for Medical Informatics, The Usher Institute, University of Edinburgh). Jake Dunning, Maria Zambon (National Infection Service, Public Health England). Ana da Silva Filipe, Antonia Ying Wai Ho, Massimo Palmarini, David L Robertson, Janet T Scott, Emma C Thomson, Sarah E McDonald (Medical Research Council [MRC]-University of Glasgow Centre for Virus Research, University of Glasgow). Tom Fletcher (Liverpool School of Tropical Medicine). Christoper A Green (Institute of Microbiology and Infection, University of Birmingham). Julian A Hiscox (Institute of Infection and Global Health, University of Liverpool). Peter W Horby (Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford). Samreen Ijaz (Virology Reference Department, National Infection Service, Public Health England). Saye Khoo (Department of Pharmacology, University of Liverpool). Paul Klenerman (Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford). Andrew Law (The Roslin Institute, University of Edinburgh). Wei Shen Lim (Nottingham University Hospitals NHS Trust). Alexander J Mentzer (Nuffield Department of Medicine, John Radcliffe Hospital, Oxford). Alison M Meynert, Murray Wham (MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh). Mahdad Noursadeghi (Division of Infection and Immunity, University College London). Shona C Moore, William A Paxton, Georgios Pollakis (Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool). Nicholas Price (Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London). Andrew Rambaut (Institute of Evolutionary Biology, University of Edinburgh). Vanessa Sancho-Shimizu (Department of Pediatrics and Virology, Imperial College London). Thushan de Silva (The Florey Institute for Host-Pathogen Interactions, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield). David Stuart (Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford). Charlotte Summers (Department of Medicine, University of Cambridge, Cambridge). Richard S Tedder (Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England). AA Roger Thompson (Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield). Rishi K Gupta (Institute for Global Health, University College London). Carlo Palmieri (Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool). Olivia V Swann (Department of Child Life and Health, University of Edinburgh). Marc-Emmanuel Dumas, Julian L Griffin, Zoltan Takats, Petros Andrikopoulos, Anthonia Osagie, Michael Olanipekun, Sonia Liggi (Department of Metabolism, Digestion and Reproduction, Imperial College London). Kanta Chechi (Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London). Matthew R Lewis, Gonçalo dos Santos Correia, Caroline J Sands, Panteleimon Takis, Lynn Maslen (National Phenome Centre, Department of Metabolism, Digestion and Reproduction, Imperial College London). Chloe Donohue, Jo Dalton, Michelle Girvan, Egle Saviciute, Stephanie Roberts, Janet Harrison, Laura Marsh, Marie Connor, Sophie Halpin, Clare Jackson, Carrol Gamble (Liverpool Clinical Trials Centre, University of Liverpool). Gary Leeming (Centre for Health Informatics, Division of Informatics, Imaging and Data Science, School of Health Sciences, University of Manchester). William Greenhalf (Department of Molecular and Clinical Cancer Medicine, University of Liverpool). Victoria Shaw (Institute of Translational Medicine, University of Liverpool, Liverpool, Merseyside, United Kingdom). Seán Keating (Intensive Care Unit, Royal Infirmary Edinburgh). Carlo Palmieri (University of Liverpool). Katie A Ahmed, Jane A Armstrong, Milton Ashworth, Innocent G Asiimwe, Siddharth Bakshi, Samantha L Barlow, Laura Booth, Benjamin Brennan, Katie Bullock, Nicola Carlucci, Emily Cass, Benjamin WA Catterall, Jordan J Clark, Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarslan, Alejandra Doce Carracedo, Chris Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lorna Finch, Lewis WS Fisher, Lisa Flaherty, Terry Foster, Isabel Garcia-Dorival, William Greenhalf, Philip Gunning, Catherine Hartley, Anthony Holmes, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia Khandaker, Katharine King, Robyn T. Kiy, Chrysa Koukorava, Annette Lake, Suzannah Lant, Diane Latawiec, Lara Lavelle-Langham, Daniella Lefteri, Lauren Lett, Lucia A Livoti, Maria Mancini, Hannah Massey, Nicole Maziere, Sarah McDonald, Laurence McEvoy, John McLauchlan, Soeren Metelmann, Nahida S Miah, Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah Penrice-Randal, Jack Pilgrim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales, Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S Subramaniam, Agnieska Szemiel, Aislynn Taggart, Jolanta Tanianis-Hughes, Jordan Thomas, Erwan Trochu, Libby van Tonder, Eve Wilcock, J. Eunice Zhang (Outbreak Laboratory, University of Liverpool). Kayode Adeniji, Daniel Agranoff, Ken Agwuh, Dhiraj Ail, Erin L Aldera, Ana Alegria, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher Bassford, Sneha Basude, David Baxter, Michael Beadsworth, Jolanta Bernatoniene, John Berridge, Nicola Best, Pieter Bothma, Robin Brittain-Long, Naomi Bulteel, Tom Burden, Andrew Burtenshaw, Vikki Caruth, David Chadwick, David Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, Srikanth Chukkambotla, Tom Clark, Paul Collini, Catherine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-Moguel, Paul Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam Douthwaite, Andrew Drummond, Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans, Chi Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden, Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hobrok, Luke Hodgson, Anil Hormis, Michael Jacobs, Susan Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandian, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri Koduri, George Koshy, Shondipon Laha, Steven Laird, Susan Larkin, Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little, Mark Lyttle, Michael MacMahon, Emily MacNaughton, Ravish Mankregod, Huw Masson, Elijah Matovu, Katherine McCullough, Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Mariyam Mirfenderesky, Kavya Mohandas, Quen Mok, James Moon, Elinoor Moore, Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbiye Mpenge, Rohinton Mulla, Michael Murphy, Thapas Nagarajan, Megan Nagel, Mark Nelson, Lillian Norris, Matthew K. O’Shea, Marlies Ostermann, Igor Otahal, Mark Pais, Selva Panchatsharam, Danai Papakonstantinou, Padmasayee Papineni, Hassan Paraiso, Brij Patel, Natalie Pattison, Justin Pepperell, Mark Peters, Mandeep Phull, Stefania Pintus, Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alistair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, Sarah Cole, Aarti Shah, Manu Shankar-Hari, Prad Shanmuga, Anil Sharma, Anna Shawcross, Jagtur Singh Pooni, Jeremy Sizer, Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines, Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascanio Tridente, Darell Tupper-Carey, Mary Twagira, Nick Vallotton, Rama Vancheeswaran, Lisa Vincent-Smith, Shico Visuvanathan, Alan Vuylsteke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Meme Wijesinghe, Martin Williams, Lawrence Wilson, Stephen Winchester, Martin Wiselka, Adam Wolverson, Daniel G Wootton, Andrew Workman, Bryan Yates, Peter Young (local principal investigators).
Data sharing
Declaration of interests
ABD reports grants from the Department of Health and Social Care (DHSC), during the conduct of the study; and grants from Wellcome Trust, outside the submitted work. PJMO reports institutional fees from consultancies from Janssen, Oxford Immunotech, Nestle, Pfizer, and the European Respiratory Society; grants from the MRC, MRC Global Challenge Research Fund, EU, NIHR Biomedical Research Centre, MRC, GlaxoSmithKline, Wellcome Trust, and NIHR Health Protection Research Unit (HPRU) in Respiratory Infection; and is NIHR senior investigator outside the submitted work. PJMO’s role as president of the British Society for Immunology was unpaid but travel and accommodation at some meetings was provided by the Society.JKB reports grants from MRC UK. MGS reports grants from DHSC, NIHR UK, MRC UK, HPRU in Emerging and Zoonotic Infections, and University of Liverpool, during the conduct of the study; and is chair of the Infectious Diseases Science Advisory Board and minority shareholder of Integrum Scientific, Greensboro NC, outside the submitted work. All other authors declare no competing interests.
Acknowledgments
This work is supported by grants from: the NIHR (award CO-CIN-01), MRC (grant MC_PC_19059), NIHR Imperial Biomedical Research Centre (grant P45058), HPRU in Respiratory Infections at Imperial College London, and NIHR HPRU in Emerging and Zoonotic Infections at the University of Liverpool, in partnership with Public Health England (NIHR award 200907), Wellcome Trust, Department for International Development (215091/Z/18/Z), Bill & Melinda Gates Foundation (OPP1209135), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (IS-BRC-1215–20013), EU Platform for European Preparedness Against (Re-) Emerging Epidemics (PREPARE; FP7 project 602525). NIHR Clinical Research Network provided the infrastructure support for this research. LT is a Wellcome Trust clinical career development fellow, supported by grant number 205228/Z/16/Z. This research was funded in part by the Wellcome Trust. PJMO is supported by an NIHR Senior Investigator Award (award 201385). The views expressed are those of the authors and not necessarily those of the DHSC, Department for International Development, NIHR, MRC, Wellcome Trust, or Public Health England. This work uses data provided by patients and collected by the National Health Service (NHS) as part of their care and support. We are extremely grateful to the 2648 front-line NHS clinical and research staff and volunteer medical students, who collected this data in challenging circumstances, and the generosity of the participants and their families for their individual contributions in these difficult times. We also acknowledge the support of Jeremy J Farrar and Nahoko Shindo.
Supplementary Material
References
- 1.
Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.
BMJ. 2020; 369m1985
- 2.
Persistent symptoms in patients after acute COVID-19.
JAMA. 2020; 324: 603-605
- 3.
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings.
Brain. 2020; 143: 3104-3120
- 4.
Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).
JAMA Cardiol. 2020; ()
- 5.
The functional costs of ICU survivorship. Collaborating to improve post-ICU disability.
Am J Respir Crit Care Med. 2011; 183: 962-964
- 6.
Five-year mortality and hospital costs associated with surviving intensive care.
Am J Respir Crit Care Med. 2016; 194: 198-208
- 7.
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study.
Lancet. 2020; 396: 27-38
- 8.
Early troponin I in critical illness and its association with hospital mortality: a cohort study.
Crit Care. 2017; 21: 216
- 9.
Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury.
Circulation. 2018; 137: 1236-1245
- 10.
Survivors of acute respiratory distress syndrome: relationship between pulmonary dysfunction and long-term health-related quality of life.
Crit Care Med. 2005; 33: 1549-1556
- 11.
Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland.
Eur Respir J. 2018; 51: 51
- 12.
Open source clinical science for emerging infections.
Lancet Infect Dis. 2014; 14: 8-9
- 13.
Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19.
- 14.
Site set-up.
- 15.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
PLoS Med. 2007; 4: e296
- 16.
Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support.
J Biomed Inform. 2009; 42: 377-381
- 17.
Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury.
Kidney International Supplements. 2012; 2: 1-138
- 18.
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.
BMJ. 2020; 370m3339
- 19.
Acute kidney injury: short-term and long-term effects.
Crit Care. 2016; 20: 188
- 20.
AKI and long-term risk for cardiovascular events and mortality.
J Am Soc Nephrol. 2017; 28: 377-387
- 21.
Long-term prognosis of acute kidney injury after acute myocardial infarction.
Arch Intern Med. 2008; 168: 987-995
- 22.
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet. 2018; 392: 1789-1858
- 23.
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet Neurol. 2019; 18: 459-480
- 24.
Cerebral performance category and long-term prognosis following out-of-hospital cardiac arrest.
Crit Care Med. 2013; 41: 1252-1257
- 25.
Critical care and the global burden of critical illness in adults.
Lancet. 2010; 376: 1339-1346
- 26.
Acute kidney injury and adverse outcomes of critical illness: correlation or causation?.
Clin Kidney J. 2019; 13: 133-141
- 27.
Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection.
Crit Care. 2011; 15: R66
- 28.
Liver involvement during influenza infection: perspective on the 2009 influenza pandemic.
Influenza Other Respir Viruses. 2012; 6: e2-e5
- 29.
Influenza virus-related critical illness: pathophysiology and epidemiology.
Crit Care. 2019; 23: 258
- 30.
The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis.
Influenza Other Respir Viruses. 2016; 10: 394-403
- 31.
Risk for in-hospital complications associated with covid-19 and influenza – veterans health administration, United States, October 1, 2018–May 31, 2020.
MMWR Morb Mortal Wkly Rep. 2020; 69: 1528-1534
- 32.
Weekly coronavirus disease 2019 (COVID-19) surveillance report—summary of COVID-19 surveillance systems.
- 33.
Coronavirus: top scientists call for herd immunity approach—as government’s ‘soft touch’ criticised.
- 34.
Description and proposed management of the acute COVID-19 cardiovascular syndrome.
Circulation. 2020; 141: 1903-1914
- 35.
Liver injury in COVID-19: the current evidence.
United European Gastroenterol J. 2020; 8: 509-519
- 36.
Gastrointestinal complications in critically ill patients with and without COVID-19.
JAMA. 2020; 324: 1899-1901
- 37.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020; 395: 1054-1062
- 38.
Acute kidney injury in patients with severe COVID-19 in Mexico.
PLoS One. 2021; 16e0246595
- 39.
COVID-19 reports.
- 40.
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
J Thromb Haemost. 2020; 18: 1743-1746
- 41.
Cardiovascular implications of COVID-19 versus influenza infection: a review.
BMC Med. 2020; 18: 403
- 42.
Covid-19: why Germany’s case fatality rate seems so low.
BMJ. 2020; 369m1395
- 43.
Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study.
Clin Microbiol Infect. 2020; 26: 1663-1669
- 44.
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients.
Sci Rep. 2020; 1020731
- 45.
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.
Lancet Respir Med. 2021; 9: 251-259
Article Info
Publication History
Identification
Copyright
© 2021 The Author(s). Published by Elsevier Ltd.
User License
ScienceDirect
Linked Articles
- In-hospital complications associated with COVID-19
-
As the COVID-19 pandemic persists globally,1 an emerging challenge is the shift from acute infection to the burden of long-term consequences resulting from the disease. Although a consensus terminology has not yet been reached, the post-acute stage of COVID-19 is mostly defined as 3 or 4 weeks after symptom onset, and long or chronic COVID-19 is defined as symptoms and abnormalities persisting or presenting beyond 12 weeks.2,3 Most studies have focused on acute and subacute COVID-19, although evidence-based guidance for the management of long COVID-19 is limited.
- Full-Text
-
- Department of Error
-
Drake TM, Riad AM, Fairfield CJ, et al. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre, cohort study. Lancet 2021; 398: 223–37—In the Summary of this Article, the percentage of gastrointestinal or liver complications reported should have been 10·8%. This correction has been made to the online version as of July 29, 2021.
- Full-Text
Open Access
-